ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Consumer Products

GSK buys out Novartis in OTC venture

by Ryan Cross
April 2, 2018 | APPEARED IN VOLUME 96, ISSUE 14

GlaxoSmithKline will spend $13 billion to buy Novartis’s 36.5% stake in the two drug companies’ consumer health care venture. GSK will fully own a business that includes Sensodyne toothpaste and over-the-counter pills. Vasant Narasimhan, Novartis’s new CEO, says the sale will help fuel his firm’s strategy of buying smaller pharmaceutical companies. The news came less than a week after GSK and Reckitt Benckiser both dropped out of the bidding for Pfizer’s consumer health care business, which Pfizer hopes to sell for $20 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment